Can papilloma virus testing be used to improve cervical cancer screening?

This report investigates different options for using human papillomavirus (HPV) testing in cervical cancer prevention. These options are evaluated by a stochastic model of the progression of pre‐malignancy and its relationship to HPV infection. Three screening policies are compared: 2 based on cytological screening, with or without HPV testing, and I in which HPV testing is the primary screening method. A policy of HPV testing for women with mildly abnormal smears would have little effect on the overall incidence of invasive cancer when compared with a policy of repeat cytology, provided follow‐up is efficient. Moreover, the potential value of HPV testing as a primary screening method is strongly dependent on the proportion of neoplasias that are HPV‐negative. Important factors in assessing the future role of HPV testing would be cost‐effectiveness and benefits from improved compliance. © 1996 Wiley‐Liss, Inc.

[1]  P. Woolley,et al.  Experience in Sheffield: Follow-Up of Abnormal Cervical Cytology , 1990, International journal of STD & AIDS.

[2]  S Gallivan,et al.  Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. , 1994, Journal of clinical pathology.

[3]  F. X. Bosch,et al.  HPV and cervical neoplasia: review of case-control and cohort studies. , 1992, IARC scientific publications.

[4]  H. Jones,et al.  Self‐Administered Cervical Cancer Screening , 1992, Clinical obstetrics and gynecology.

[5]  J. Cuzick,et al.  PROGRESSIVE POTENTIAL OF MILD CERVICAL ATYPIA: PROSPECTIVE CYTOLOGICAL, COLPOSCOPIC, AND VIROLOGICAL STUDY , 1986, The Lancet.

[6]  A. Singer,et al.  CIN 3: the role of lesion size in invasion , 1992, British journal of obstetrics and gynaecology.

[7]  J. Cuzick,et al.  Human papillomavirus testing in primary cervical screening , 1995, The Lancet.

[8]  J. T. Cox,et al.  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. , 1995, American journal of obstetrics and gynecology.

[9]  H. Mitchell,et al.  Adherence to recommendations for early repeat cervical smear tests. , 1989, BMJ.

[10]  J. Mills,et al.  Interferon therapy for condylomata acuminata. , 1986, The New England journal of medicine.

[11]  C. Meijer,et al.  Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. , 1992, IARC scientific publications.

[12]  L. Brinton,et al.  Screening for cervical cancer in Latin America: a case-control study. , 1992, International journal of epidemiology.

[13]  Neville F. Hacker,et al.  The Papanicolaou smear histories of 237 patients with cervical cancer , 1992 .

[14]  R. Richart,et al.  A follow-up study of patients with cervical dysplasia. , 1969, American journal of obstetrics and gynecology.

[15]  A. Elkind,et al.  Making cervical screening work. , 1989, BMJ.

[16]  P. V. van Diest,et al.  Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age‐dependent , 2009, International journal of cancer.

[17]  L. Koutsky,et al.  Natural history and epidemiological features of genital HPV infection. , 1992, IARC scientific publications.

[18]  J. L. Benedet,et al.  A comprehensive program for cervical cancer detection and management. , 1992, American journal of obstetrics and gynecology.

[19]  Jones Rw,et al.  The invasive potential of carcinoma in situ of the cervix. , 1984 .

[20]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[21]  A. Herbst.  The Bethesda System for Cervical/Vaginal Cytologic Diagnoses , 1992, Clinical obstetrics and gynecology.